Prevalence and Risk Factors of Germline Pathogenic Variants in Pancreatic Ductal Adenocarcinoma
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose The genetic attribution for pancreatic ductal adenocarcinoma (PDAC) has been reported as 5%-10%. However, the incidence of germline pathogenic variants (PVs) in Korean PDAC patients has not been thoroughly investigated. Therefore, we studied to identify the risk factors and prevalence of PV for future treatment strategies in PDAC. Materials and Methods Total of 300 (155 male) patients with a median age of 65 years (range, 33 to 90 years) were enrolled in National Cancer Center in Korea. Cancer predisposition genes, clinicopathologic characteristics, and family history of cancer were analyzed. Results PVs were detected in 20 patients (6.7%, median age 65) in ATM (n=7, 31.8%), BRCA1 (n=3, 13.6%), BRCA2 (n=3), and RAD51D (n=3). Each one patient showed TP53, PALB2, PMS2, RAD50, MSH3, and SPINK1 PV. Among them, two likely PVs were in ATM and RAD51D, respectively. Family history of various types of cancer including pancreatic cancer (n=4) were found in 12 patients. Three patients with ATM PVs and a patient with three germline PVs (BRCA2, MSH3, and RAD51D) had first-degree relatives with pancreatic cancer. Familial pancreatic cancer history and PVs detection had a significant association (4/20, 20% vs. 16/264, 5.7%; p=0.035). Conclusion Our study demonstrated that germline PVs in ATM, BRCA1, BRCA2, and RAD51D are most frequent in Korean PDAC patients and it is comparable to those of different ethnic groups. Although this study did not show guidelines for germline predisposition gene testing in patients with PDAC in Korea, it would be emphasized the need for germline testing for all PDAC patients.
Abstract
Purpose The genetic attribution for pancreatic ductal adenocarcinoma (PDAC) has been reported as 5%-10%. However, the incidence of germline pathogenic variants (PVs) in Korean PDAC patients has not been thoroughly investigated. Therefore, we studied to identify the risk factors and prevalence of PV for future treatment strategies in PDAC. Materials and Methods Total of 300 (155 male) patients with a median age of 65 years (range, 33 to 90 years) were enrolled in National Cancer Center in Korea. Cancer predisposition genes, clinicopathologic characteristics, and family history of cancer were analyzed. Results PVs were detected in 20 patients (6.7%, median age 65) in ATM (n=7, 31.8%), BRCA1 (n=3, 13.6%), BRCA2 (n=3), and RAD51D (n=3). Each one patient showed TP53, PALB2, PMS2, RAD50, MSH3, and SPINK1 PV. Among them, two likely PVs were in ATM and RAD51D, respectively. Family history of various types of cancer including pancreatic cancer (n=4) were found in 12 patients. Three patients with ATM PVs and a patient with three germline PVs (BRCA2, MSH3, and RAD51D) had first-degree relatives with pancreatic cancer. Familial pancreatic cancer history and PVs detection had a significant association (4/20, 20% vs. 16/264, 5.7%; p=0.035). Conclusion Our study demonstrated that germline PVs in ATM, BRCA1, BRCA2, and RAD51D are most frequent in Korean PDAC patients and it is comparable to those of different ethnic groups. Although this study did not show guidelines for germline predisposition gene testing in patients with PDAC in Korea, it would be emphasized the need for germline testing for all PDAC patients.
참고문헌 (29)
- Sung H, "Global cancer statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 71, pp.209~249 (2021)
- "National Cancer Information Center" (2019)[URL]
- Tempero MA, "Pancreatic adenocarcinoma, version 2. 2021, NCCN clinical practice guidelines in oncology", J Natl Compr Canc Netw, 19, pp.439~457 (2021)
- Abe K, "Hereditary pancreatic cancer", Int J Clin Oncol, 26, pp.1784~1792 (2021)
- Okur V, "The impact of hereditary cancer gene panels on clinical care and lessons learned", Cold Spring Harb Mol Case Stud, 3, pp.a002154~ (2017)
- Tempero MA, "NCCN guidelines updates : pancreatic cancer", J Natl Compr Canc Netw, 17, pp.603~605 (2019)
- Daly MB, "Genetic", familial high-risk assessment : breast, ovarian, and pancreatic, version 2. 2021, NCCN clinical practice guidelines in oncology, 2021, pp.19, 77~102
- Astiazaran-Symonds E, "A systematic review of the prevalence of germline pathogenic variants in patients with pancreatic cancer", J Gastroenterol, 56, pp.713~721 (2021)
- DePristo MA, "A framework for variation discovery and genotyping using next-generation DNA sequencing data", Nat Genet, 43, pp.491~498 (2011)
- "Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM" (2013)[URL]
- McKenna A, "The Genome Analysis Toolkit : a MapReduce framework for analyzing next-generation DNA sequencing data", Genome Res, 20, pp.1297~1303 (2010)
- Li H, "A statistical framework for SNP calling, mutation discovery, association mapping and population genetical para-meter estimation from sequencing data", Bioinformatics, 27, pp.2987~2993 (2011)
- "Haplotype-based variant detection from short-read sequencing" (2012)[URL]
- McLaren W, "The Ensembl Variant Effect Predictor", Genome Biol, 17, pp.122~ (2016)
- Liu X, "dbNSFP v3. 0 : a one-stop database of functional predictions and annotations for human nonsynonymous and splice-site SNVs", Hum Mutat, 37, pp.235~241 (2016)
- "cBioPortal for Cancer Genomics" (2022)[URL]
- Richards S, "Standards and guidelines for the interpretation of sequence variants : a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology", Genet Med, 17, pp.405~424 (2015)
- Hu C, "Prevalence of pathogenic mutations in cancer predisposition genes among pancreatic cancer patients", Cancer Epidemiol Biomarkers Prev, 25, pp.207~211 (2016)
- Hu C, "Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer", JAMA, 319, pp.2401~2409 (2018)
- Shindo K, "Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma", J Clin Oncol, 35, pp.3382~3390 (2017)
- Chaffee KG, "Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history", Genet Med, 20, pp.119~127 (2018)
- Yurgelun MB, "Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer", Genet Med, 21, pp.213~223 (2019)
- Earl J, "A comprehensive analysis of candidate genes in familial pancreatic cancer families reveals a high frequency of potentially pathogenic germline variants", EBioMedicine, 53, pp.102675~ (2020)
- Wieme G, "Prevalence of germline pathogenic variants in cancer predisposing genes in Czech and Belgian pancreatic cancer patients", Cancers(Basel), 13, pp.4430~ (2021)
- Lee K, "Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma : a prospective study evaluating risk category for genetic testing", Invest New Drugs, 36, pp.163~169 (2018)
- Park JH, "BRCA 1", 2 germline mutation predicts the treatment response of FOLFIRINOX with pancreatic ductal adenocarcinoma in Korean patients, 2022, pp.14, 236~
- National Health Insurance Act, "Approval from Ministry of Health and Welfare (Notice 2020-135) (2020 Jul 1)", ~ (2020)
- Vidula N, "Routine plasma-based genotyping to comprehensively detect germline, somatic, and reversion BRCA mutations among patients with advanced solid tumors", Clin Cancer Res, 26, pp.2546~2555 (2020)
- Walker EJ, "The additional diagnostic benefit of pancreatic cancer molecular profiling after germline testing", Pancreas, 51, pp.302~304 (2022)